Document Type

Article

Publication Date

4-1-2017

Identifier

DOI: 10.2217/pgs-2016-0185

Abstract

AIM: Therapy with low-dose amitriptyline is commonly used to treat painful diabetic peripheral neuropathy. There is a knowledge gap, however, regarding the role of variable CYP2D6-mediated drug metabolism and side effects (SEs). We aimed to generate pilot data to demonstrate that SEs are more frequent in patients with variant CYP2D6 alleles.

METHOD: To that end, 31 randomly recruited participants were treated with low-dose amitriptyline for painful diabetic peripheral neuropathy and their CYP2D6 gene sequenced.

RESULTS: Patients with predicted normal or ultra-rapid metabolizer phenotypes presented with less SEs compared with individuals with decreased CYP2D6 activity.

CONCLUSION: Hence, CYP2D6 genotype contributes to treatment outcome and may be useful for guiding drug therapy. Future investigations in a larger patient population are planned to support these preliminary findings.

Journal Title

Pharmacogenomics

Volume

18

Issue

5

First Page

433

Last Page

443

MeSH Keywords

Amitriptyline; Analgesics, Non-Narcotic; Cytochrome P-450 CYP2D6; Diabetic Neuropathies; Genotype; Humans; Pilot Projects; Random Allocation; Treatment Outcome

Keywords

CYP2D6; activity score; adverse drug reactions; amitriptyline; diabetic neuropathy

Share

COinS